Last reviewed · How we verify

Olaparib tablet

Fondazione Ricerca Traslazionale · Phase 3 active Small molecule

Olaparib inhibits poly(ADP-ribose) polymerase (PARP) enzymes, preventing DNA repair in cancer cells and causing cell death.

Olaparib tablet is a PARP (poly-ADP-ribose polymerase) inhibitor developed by Fondazione Ricerca Traslazionale, currently in Phase 3 clinical development. The drug works by inhibiting PARP enzymes, which are critical for DNA repair in cancer cells, particularly those with BRCA mutations or homologous recombination deficiency (HRD). Olaparib has demonstrated clinical efficacy across multiple cancer types including ovarian, breast, prostate, and lung cancers, with regulatory approvals already established in several jurisdictions under the brand name LYNPARZA (marketed by AstraZeneca). The compound represents a best-in-class PARP inhibitor with extensive clinical validation through 50 trials spanning Phase 1–4 and post-marketing surveillance, showing differentiation through combination strategies with immunotherapy and chemotherapy. Commercial significance is substantial, with LYNPARZA generating multi-billion dollar revenues globally, though the specific Phase 3 program by Fondazione Ricerca Traslazionale may represent a regional or indication-specific development pathway. Pipeline expansion includes combinations with checkpoint inhibitors (pembrolizumab), targeted agents (abiraterone), and radiation therapy across solid tumors.

At a glance

Generic nameOlaparib tablet
Also known asLynparza
SponsorFondazione Ricerca Traslazionale
Drug classPARP inhibitor
TargetPARP1, PARP2
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

PARP inhibitors block the repair of single-strand DNA breaks in cancer cells. In tumors with BRCA1/2 mutations or homologous recombination deficiency, this leads to accumulation of DNA damage and synthetic lethality. Olaparib is particularly effective in cancers that rely on BRCA-mediated DNA repair pathways.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: